BOARD OF DIRECTORS

Our Board comprises nine Directors, including four executive Directors, one non-executive Director and four independent non-executive Directors. The following table sets forth information in relation to our Directors:

Name	Age	Position(s)	Date of Joining Our Company	Date of Appointment as Director	Roles and Responsibilities	Relationship with Other Directors or Senior Management Members
Mr. Li Yuliang (李雨亮)	45	Chairman of the Board, executive Director and general manager	September 26, 2016	April 10, 2021	Responsible for overall strategic planning of our Company and leading our Board	Spouse of Ms. Wang Hongmei (王紅嵋)
Dr. Daniel Yunlong Du	62	Executive Director, Deputy General Manager and chief medical officer	March 1, 2021	April 10, 2021	Responsible for supervising clinical development strategy and execution, and overall R&D strategy and project planning of our Company	None
Mr. Wu Xing (毋興)	48	Executive Director, Chief Financial Officer, Board Secretary, and one of the joint company secretaries	September 26, 2016	April 10, 2021	Responsible for supervising corporate investment and financing activities, overall financial planning, and investor relations management of our Company	None
Ms. Wang Hongmei (王紅嵋)	46	Executive Director	May 28, 2020	May 28, 2020	Responsible for overseeing the operation and daily management of our Company	Spouse of Mr. Li Yuliang (李雨亮)
Dr. Han Yongxin (韓永信)	60	Non-executive Director	September 1, 2018	May 28, 2020	Responsible for providing strategic and industry-level advice to the Board	None
Mr. Zhang Qing (張青)	47	Independent non-executive Director	January 23, 2025	January 23, 2025	Responsible for providing independent advice and judgment to our Board	None

Name	Age	Position(s)	Date of Joining Our Company	Date of Appointment as Director	Roles and Responsibilities	Relationship with Other Directors or Senior Management Members
Mr. Na Shuai (那帅)	38	Independent non-executive Director	January 23, 2025	January 23, 2025	Responsible for providing independent advice and judgment to our Board	None
Mr. Hu Wei (胡威) . .	43	Independent non-executive Director	January 23, 2025	January 23, 2025	Responsible for providing independent advice and judgment to our Board	None
Mr. Lang Xiaofeng (郎晓峰) .	44	Independent non-executive Director	[●]	[●]	Responsible for providing independent advice and judgment to our Board	None

Executive Directors

Mr. Li Yuliang (李雨亮), aged 45, is the chairman of the Board, an executive Director and general manager of our Company. Mr. Li founded our Company in September 2016 and has served as the executive Director and chairman of our Board since April 2021, and the Company's legal representative since February 2022 and was appointed as the general manager of the Company in January 2025. He is primarily responsible for overall strategic planning of our Company and leading our Board. He is also one of our Controlling Shareholders and the spouse of Ms. Wang. As the core strategic leader of the Company, Mr. Li led the company's R&D direction, built the early R&D team and introduced key talents, making final core decisions on pipeline initiation, clinical strategies and external project introductions. Mr. Li also organized pre-clinical technical platform establishment, led clinical development strategy formulation and resource coordination, and leveraged his commercial background to lead commercial strategy, channel layout and high-level BD negotiations for several products of our Company (e.g., our Core Product Pumecitinib).

Prior to founding our Company, Mr. Li accumulated extensive experience and a successful track record across the broader healthcare industry. Mr. Li has particular experience and industry resources within the pharmaceutical and medical sectors, enabling him with a forward-looking business perspective critical to the integrated health field. Mr. Li has over 18 years of experience in corporate and business management. From October 2007 to July 2011, he served as an executive director and manager of Chifeng Jinquan Health Technology Co., Ltd. (赤峰金泉健康科技有限公司), formerly known as Chifeng Jinquan Electronic Products Co., Ltd.* (赤峰金泉電子產品有限公司), a company that is primarily engaged in production and sales of electronic products. From April 2011 to April 2025, he was the executive director and manager at Chifeng Saliont Pharmaceutical Co., Ltd.* (赤峰賽林泰藥業有限公司), a company that is primarily engaged in production and sales of drugs. In January 2016, Mr Li established Chifeng Fukang Investment Management Co., Ltd. (赤峰福康投資管理有限公司) ("**Chifeng Fukang Investment**"), which primarily engages in investment and operations within the comprehensive health business sector. Through Chifeng Fukang Investment, Mr. Li acquired interests in Chifeng Meinian Healthcare Management Co., Ltd. (赤峰美年大健康健康管理有限公司), a company primarily engages in body check and consulting services in April 2016. In March 2017, Mr. Li indirectly founded Chifeng Ciming Healthcare

Management Co., Ltd. (赤峰慈銘健康管理有限公司), which primarily engages in body check and consulting services. In June 2019, he indirectly founded Chifeng Jinfu Real Estate Development Co., Ltd. (赤峰晋福房地開發有限公司), which primarily engages in the wellness-integrated real estate business. In May 2020, he indirectly founded Chifeng Qinghe Hospital (赤峰清河醫院), a private secondary general hospital specializing in chronic disease rehabilitation services.

Mr. Li served as a director, legal representative or the general manager of the following companies, which were established in the PRC, at the time or within 12 months from the time of their deregistration or revocation of business license. The relevant details are as follows:

Name of Enterprise	Place of Incorporation	Status	Date of Dissolution	Reason of Dissolution	Position held
Beijing Huanxiang Vision Culture Media Co., Ltd. (北京幻想視覺文化傳媒有限公司)	PRC	Deregistration	August 11, 2021	Revocation of business license[(1)]	Chairman of the board and legal representative
Chifeng Zhirong Investment Co., Ltd. (赤峰智榮投資有限公司)	PRC	Deregistration	March 31, 2016	Cessation of business operation	Executive director, general manager and legal representative
Shanghai Aoyun Software Co., Ltd. (上海奧雲軟件有限公司)	PRC	Deregistration	March 22, 2019	Cessation of business operation	Executive director, general manager and legal representative
Chifeng Puqi Pharmaceutical Technology Co., Ltd. (赤峰普祺醫藥科技有限公司)	PRC	Deregistration	July 25, 2022	Cessation of business operation	Executive director, general manager and legal representative

Note:

1. The business license of Beijing Huanxiang Vision Culture Media Co., Ltd. (北京幻想視覺文化傳媒有限公司) was revoked by the regulatory authority as it has been voluntarily in a state of suspension with no business activities carried out for more than six months and has not applied to the regulatory authority for suspension registration, which pursuant to the PRC laws gives rise to a cause of matter for revocation of business license.

As confirmed by Mr. Li, to the best of his knowledge, (i) the aforesaid companies were solvent immediately prior to their dissolution or revocation of business license, (ii) there was no wrongful act on his part leading to the dissolution or revocation of business license, (iii) the aforesaid companies have been fully dissolved and no contingent liabilities, outstanding obligations, or potential claims remain, (iv) he is not aware of any actual or potential claim that has been or will be made against him as a result of the dissolution or revocation of business license, and (v) there is no contingent liability, unresolved regulatory issue, or potential or ongoing litigation involving Mr. Li or the aforesaid companies in consequence of such dissolution or revocation of business license.

Mr. Li graduated from Hebei Finance University, majoring in finance in the PRC in July 2002.

Dr. Daniel Yunlong Du, aged 62, is an executive Director and deputy general manager of our Company. Dr. Du has been appointed as chief medical officer since April 2021. He has been appointed as Director since April 2021. He was further appointed as general manager from March 2021 to January 2025 and was appointed as a deputy general manager in January 2025. He is primarily responsible for supervising clinical development strategy and execution, and overall R&D strategy and project planning of our Company.

Dr. Du has over 20 years of extensive experience in the pharmaceutical and healthcare R&D industry. Dr. Du held position at Pfizer Inc., a multinational pharmaceutical company headquartered in New York from August 2002 to August 2007 with his last position as the associate director. From October 2009 to August 2015, he was the principal clinical scientist at GlaxoSmithKline Plc., a multinational pharmaceutical company headquartered in the United Kingdom. From November 2015 to March 2016, he served at Akebia Therapeutics, Inc., a pharmaceutical company in Massachusetts in the United States. From March 2016 to August 2017, he worked as the vice president at Frontage Clinical Services, Inc., a company engaged in drug development studies in New Jersey in the United States. From November 2017 to March 2021, Dr. Du worked at Hualing Pharmaceuticals Technology (Shanghai) Co., Ltd. (華領醫藥技術(上海)有限公司), a company listed on The Stock Exchange of Hong Kong Limited (stock code: 02552.HK), as the senior vice president.

Dr. Du obtained his bachelor's degree in medicine and a master's degree in medicine with a major in basic medical science and pharmacology from Peking Medical University (北京醫科大學), now known as the Peking University Health Science Center (北京大學醫學部), in the PRC in July 1987 and July 1989 respectively. He attended Albany Medical College from August 1990, majoring in pharmacology and toxicology, and was awarded a doctor of philosophy degree by the institution, in the United States of America in May 1995.

Mr. Wu Xing (毋興), aged 48, is an executive Director, Chief Financial Officer, Board Secretary and one of the joint company secretaries of our Company. Mr. Wu was appointed as manager from September 2016 to May 2020. He was further appointed as the supervisor from May 2020 to April 2021. He was appointed as a Director in April 2021, appointed as the chief financial officer in August 2023 and appointed as Board secretary in January 2025. He is primarily responsible for supervising corporate investment and financing activities, overall financial planning, and investor relations management of our Company. Mr. Wu is also responsible for overseeing and executing various rounds of financing activities of the Company. Mr. Wu is a member of the Remuneration Committee.

Mr. Wu has over 15 years of experience in finance and investment. From February 2003 to May 2004, he worked at Beijing Zhonghongjin Information Co., Ltd. (北京中宏金資訊有限公司). From September 2008 to July 2011, he worked at China Postal Savings Bank Company Limited (Shanxi Provincial Branch) (中國郵政儲蓄銀行股份有限公司山西省分行). From September 2011 to July 2014, he worked at Bank of Communications Company Limited (Shanxi Provincial Branch) (交通銀行股份有限公司山西省分行). Subsequently, from January 2016 to March 2018, he worked as the deputy general manager at Chifeng Fukang Investment Management Co., Ltd.* (赤峰福康投資管理有限公司).

Mr. Wu served as a director, supervisor, general manager, executive partner or legal representative of the following companies, which were established in the PRC, at the time or within 12 months from the time of their deregistration. The relevant details are as follows:

Name of Enterprise	Place of Incorporation	Status	Date of Dissolution	Reason of Dissolution	Position held
Chifeng Puqi Pharmaceutical Technology Co., Ltd. (赤峰普祺醫藥科技有限公司)	PRC	Deregistration	July 25, 2022	Cessation of business operation	Supervisor
Chifeng Herun Pharmaceutical Co., Ltd. (赤峰和潤醫藥有限公司)	PRC	Deregistration	October 18, 2021	Cessation of business operation	Executive director, general manager and legal representative

Name of Enterprise	Place of Incorporation	Status	Date of Dissolution	Reason of Dissolution	Position held
Chifeng Sanyang Pharmaceutical Technology Co., Ltd. (赤峰三陽醫藥科技有限公司)	PRC	Deregistration	November 15, 2019	Cessation of business operation	Executive director, general manager and legal representative
Chifeng Hankang Medical Technology Co., Ltd. (赤峰瀚康醫療科技有限公司)	PRC	Deregistration	July 5, 2022	Cessation of business operation	Supervisor
Chifeng Hongxi Enterprise Management Consulting Centre (Limited Partnership) (赤峰鴻熙企業管理諮詢中心(有限合夥))	PRC	Deregistration	July 18, 2022	Cessation of business operation	Executive partner

As confirmed by Mr. Wu, to the best of his knowledge, (i) the aforesaid companies were solvent immediately prior to their dissolution, (ii) there was no wrongful act on his part leading to the dissolution, and (iii) he is not aware of any actual or potential claim that has been or will be made against him as a result of the dissolution.

Mr. Wu obtained his master's degree in economics, majoring in finance, from Shanxi University of Finance and Economics (山西財經大學) in the PRC in June 2008.

Ms. Wang Hongmei (王紅峋) (formerly known as Wang Hongmei (王紅梅)), aged 46, is an executive Director of our Company. Ms. Wang joined our Company in May 2020. From May 2020 to April 2022, she worked as the manager of our Company. Ms. Wang has been appointed as Director since May 28, 2020, and in August 2023 she was appointed as the head of the Board office. She is primarily responsible for overseeing the operation and daily management of our Company. Ms. Wang is a member of the Nomination Committee. Ms. Wang is the spouse of Mr. Li. As a professional executive complementary to the strategic team, Ms. Wang was primarily responsible for the daily administrative management of the Company. She assisted in commercial channel layout and business development team management, and provided practical support for each stage to ensure work efficiency and quality.

Prior to joining our Company, she worked at Chifeng Jinquan Health Technology Co., Ltd. (赤峰金泉健康科技有限公司), formerly known as Chifeng Jinquan Electronic Products Co., Ltd. (赤峰金泉電子產品有限公司), a company that is primarily engaged in production and sales of electronic products, as a supervisor from October 2007 to July 2011 and as an executive director and manager from July 2011 to November 2020.

Ms. Wang was the director, general manager or legal representative of the following dissolved companies, which were established in the PRC, at the time or within 12 months from the time of their deregistration or revocation of business license. The relevant details are as follows:

Name of Enterprise	Place of Incorporation	Status	Date of Dissolution	Reason of Dissolution	Position held
Beijing Huanxiang Vision Culture Media Co., Ltd. (北京幻想視覺文化傳媒有限公司)	PRC	Deregistration	August 11, 2021	Revocation of business license	Director

Name of Enterprise	Place of Incorporation	Status	Date of Dissolution	Reason of Dissolution	Position held
Beijing Derun Kangtai Biomedical Technology Co., Ltd. (北京德潤康泰生物醫藥科技有限公司) .	PRC	Deregistration	December 4, 2019	Cessation of business operation	Executive director, general manager and legal representative
Chifeng Aiyue Health Management Co., Ltd. (赤峰愛悅健康管理有限公司)	PRC	Deregistration	July 5, 2022	Cessation of business operation	Executive director, general manager and legal representative

As confirmed by Ms. Wang, to the best of her knowledge, (i) the aforesaid companies were solvent immediately prior to their dissolution or revocation of business license, (ii) there was no wrongful act on her part leading to the dissolution or revocation of business license, (iii) the aforesaid companies have been fully dissolved and no contingent liabilities, outstanding obligations, or potential claims remain, (iv) she is not aware of any actual or potential claim that has been or will be made against her as a result of the dissolution or revocation of business license, and (v) there is no contingent liability, unresolved regulatory issue, or potential or ongoing litigation involving Ms. Wang or the aforesaid companies in consequence of such dissolution or revocation of business license.

Ms. Wang obtained her master's degree in law from Beijing Institute of Technology (北京理工大學) in the PRC in June 2023.

Non-executive Director

Dr. Han Yongxin (韓永信), aged 60, is the non-executive Director of our Company. Dr. Han joined as a consultant since September 2018 and he was appointed as the Director of our Company in May 2020. He is primarily responsible for providing strategic and industry-level advice to the Board.

Prior to joining our Company, Dr. Han worked at Hybridon Inc., a biotechnology company based in Massachusetts, as research scientist in 1997. From November 2003 to October 2005, he worked at Array BioPharma Inc., a biopharmaceutical company in Colorado. From August 2010 to May 2016, he worked as the general manager of Centaurus BioPharma Co., Ltd. (北京賽林泰醫藥技術有限公司). Dr. Han worked at Peak Beijing Co., Ltd. (北京鼎峯科誠醫藥技術有限公司) as a supervisor from September 2015 to November 2021. From December 2016 to July 2020, he worked as the supervisor of Zhejiang Chuangxinshu Network Technology Co., Ltd. (浙江創欣樹網絡科技有限公司). From March 2018 to December 2019, he was the supervisor of Beijing Derun Kangtai Biomedical Technology Co., Ltd. (北京德潤康泰生物醫藥科技有限公司). From June 2018 to May 2023, he was the manager of Beijing Bohan Technology Development Centre (北京博涵科技發展中心). From June 2018 to May 2025, he was the director of Vivavision Biotech Inc. (維眸生物科技(浙江)有限公司). From August 2018 to present, he was the director of BroadenBio Co., Ltd. (北京伯匯生物技術有限公司). From May 2022 to January 12, 2026, he was the director of Beijing Konruns Pharmaceutical Co., Ltd. (北京康辰藥業股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 603590.SH).

Dr. Han was a supervisor or manager of the following companies, which were established in the PRC, at the time or within 12 months from the time of their deregistration. The relevant details are as follows:

Name of Enterprise*	Place of Incorporation	Status	Date of Dissolution	Reason of Dissolution	Position held
Peak Beijing Co., Ltd. (北京鼎峯科誠醫藥技術有限公司)	PRC	Deregistration	November 2, 2021	Cessation of business operation	Supervisor
Zhejiang Chuangxinshu Network Technology Co., Ltd. (浙江創欣樹網絡科技有限公司)	PRC	Deregistration	July 21, 2020	Cessation of business operation	Supervisor
Beijing Derun Kangtai Biomedical Technology Co., Ltd. (北京德潤康泰生物醫藥科技有限公司)	PRC	Deregistration	December 4, 2019	Cessation of business operation	Supervisor
Beijing Bohan Technology Development Centre (北京博涵科技發展中心)	PRC	Deregistration	May 23, 2023	Cessation of business operation	Manager

As confirmed by Dr. Han, to the best of his knowledge, (i) the aforesaid companies were solvent immediately prior to their dissolution, (ii) there was no wrongful act on his part leading to the dissolution, (iii) the aforesaid companies have been fully dissolved and no contingent liabilities, outstanding obligations, or potential claims remain, and (iv) he is not aware of any actual or potential claim that has been or will be made against him as a result of the dissolution.

Dr. Han obtained his bachelor's degree in Chemistry from the Peking University in the PRC in July 1987. He further obtained his master's degree in polymer chemistry from Institute of Chemistry, Chinese Academy of Sciences (中國科學院化學研究所) in the PRC, in September 1990. He received his doctor of philosophy degree from University of Minnesota in the United States of America in October 1996.

Dr. Han was qualified as Senior Engineer in Biopharmaceuticals (Professor-Level) (生物製藥高級工程師(教授級)) upon approved by Beijing Senior Specialized Technique Qualification Evaluation Committee (北京高級技術專業資格評審委員會) in December 2012.

Independent Non-executive Directors

Mr. Zhang Qing (張青), aged 47, was appointed as an independent non-executive Director on January 23, 2025. He is primarily responsible for providing independent advice and judgment to our Board. Mr. Zhang is a member of the audit committee.

Prior to joining our Company, Mr. Zhang worked at Nanjing Medical University (南京醫科大學) as teaching assistant from October 2004 to June 2007, as a lecturer from July 2007 to June 2019, and has served as the associate professor since July 2019. From November 2017 to November 2018, he conducted academic research as a visiting scholar at Stanford University in the United States of America.

Mr. Zhang obtained his master's degree in science from China Pharmaceutical University (中國藥科大學) in the PRC in June 2004. He received his doctor of medicine degree in pharmacology from Nanjing Medical University (南京醫科大學) in the PRC in December 2015. Since 2019, he has been recognized as an associate professor by Nanjing Medical University.

Mr. Na Shuai (那帥), aged 38, was appointed as an independent non-executive Director on January 23, 2025. He is responsible for providing independent advice and judgment to our Board. Mr. Na is the Chairman of the Nomination Committee and a member of the Audit Committee.

Mr. Na was the postdoctoral fellow at the California Institute of Technology from November 2017 to February 2022. He has served as a research fellow at Peking University since April 2022.

Mr. Na obtained a bachelor's degree in engineering from Tongji University (同濟大學) in the PRC in July 2010. He obtained a master's degree in science with a major in engineering mechanics from Fudan University (復旦大學) in the PRC in June 2013. He received his doctor of philosophy degree from University of Waterloo in Canada in October 2017.

Mr. Hu Wei (胡威), aged 43, was appointed as independent non-executive Director on January 23, 2025. He is responsible for providing independent advice and judgment to our Board. Mr. Hu is the Chairman of the Audit Committee and a member of the Remuneration Committee.

Prior to joining our Company, Mr. Hu served at Deloitte Touche Tohmatsu CPA Firm, Beijing Office (德勤華永會計師事務所(特殊普通合夥)北京分所), from July 2006 to December 2015 with his last position as senior audit manager. From January 2016 to April 2018, he served as vice president of the International Business Division at China Science & Merchants Investment Management Group Co., Ltd. (中科招商投資管理集團股份有限公司). From April 2018 to May 2019, he served as finance head at Asia Clean Capital (Beijing) New Energy Technology Ltd (亞潔能(北京)新能源科技有限公司). From December 2019 to March 2024, he was the chief financial officer and board secretary of Beijing Jiuzhou Hengsheng Electric Power Technology Co., Ltd. (北京九州恆盛電力科技有限公司). From September 2024 to April 2025, he was the chief operating officer of Beijing Jinshan Intelligent Technology Co., Ltd. (北京金山智能科技有限公司). Since May 2024, Mr. Hu has served as the assistant to the chairman of Beijing Huaxia Pawn Firm Co., Ltd. (北京市華夏典當行有限責任公司).

Mr. Hu obtained his bachelor's degree in economics from North China University of Technology (北方工業大學) in the PRC in July 2004. He obtained a master's degree in management with a major in accounting from University of International Business and Economics (對外經濟貿易大學) in the PRC in July 2006.

Mr. Hu became a non-practicing member of the Chinese Institute of Certified Public Accountants (中國註冊會計師協會) in July 2016. He became a Certified Public Accountant in the state of Illinois, in the United States of America in February 2013.

Mr. Lang Xiaofeng (郎曉峰), aged 44, is the independent non-executive Director of our Company. Mr. Lang has been appointed as an independent non-executive Director in [●]. He is primarily responsible for providing independent advice and judgment to our Board. He is the Chairman of the Remuneration Committee and a member of the Nomination Committee.

Mr. Lang held the position as a sales manager of China Railway Investment Co., Ltd. from 2009 to 2014. Mr. Lang served as the vice president of Hony Capital from December 2014 to September 2017. From September 2017 to September 2020, he served as Senior Manager of the Development Department at Home one Group Limited (弘毅集團有限公司). From September 2020 to September 2021, Mr. Lang serves as the assistant to general manager and chief company development officer (公司發展部總監) of the Hospital Corporation of China Limited (弘和仁愛醫療集團有限公司), a company listed on The Stock Exchange of Hong Kong Limited (stock code: 03869.HK). He is primarily responsible for strategic research, branding affairs, public relations and government affairs. From September 2021 to February 2025, Mr. Lang served as the senior assistant and partner of healthcare fund of Hony Capital. Since February 2025, Mr. Lang serves as the general manager and managing partner of Hony Capital.

Mr. Lang obtained his bachelor's degree in information management and information systems from Dalian University of Technology (大連理工大學) in July 2005 and his master's degree in business and information technology from the University of Melbourne (墨爾本大學) in Australia in December 2007.

Other Disclosure Pursuant to Rule 13.51(2) of the Listing Rules

Save as disclosed in this document, each of our Directors confirms with respect to himself or herself that he or she (1) did not hold other long positions or short positions in the Shares, underlying Shares, debentures of our Company or any associated corporation (within the meaning of Part XV of the SFO) as of the Latest Practicable Date; (2) had no other relationship with any Directors, senior management, Controlling Shareholder(s) or substantial shareholders of our Company as of the Latest Practicable Date; (3) did not hold any other major appointment or Directorships in the three years prior to the Latest Practicable Date in any public companies of which the securities are listed on any securities market in Hong Kong and/or overseas; and (4) there are no other matters concerning our Director's appointment that need to be brought to the attention of our Shareholders and the Stock Exchange or shall be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

CONFIRMATION FROM OUR DIRECTORS

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules on January 12, 2026, and (ii) understands his or her obligations as a Director of a listed issuer under the Listing Rules.

Rule 3.13 of the Listing Rules

Each of our independent non-executive Directors has confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules, (ii) he has no past or present financial or other interest in the business of the Company or any connection with any core connected person of the Company under the Listing Rules as of the Latest Practicable Date, and (iii) that there are no other factors that may affect his independence at the time of his appointment.

SENIOR MANAGEMENT

The table below sets out certain information regarding our senior management:

Name	Age	Position(s)	Date of joining our Company	Date of appointment as senior management member	Roles and responsibilities	Relationship with other Directors or senior management members
Mr. Li Yuliang (李雨亮) .	45	Chairman of the Board, executive Director and general manager	September 26, 2016	April 10, 2021	Responsible for overall strategic planning of our Company and leading our Board	Spouse of Ms. Wang Hongmei (王紅媚)

Name	Age	Position(s)	Date of joining our Company	Date of appointment as senior management member	Roles and responsibilities	Relationship with other Directors or senior management members
Dr. Daniel Yunlong Du	62	Executive Director, Deputy General Manager and chief medical officer	March 1, 2021	April 10, 2021	Responsible for supervising clinical development strategy and execution, and overall R&D strategy and project planning of our Company	None
Mr. Wu Xing (毋興)	48	Executive Director, Chief Financial Officer, Board Secretary and one of the joint company secretaries	September 26, 2016	April 10, 2021	Responsible for supervising corporate investment and financing activities, overall financial planning, and investor relations management of our Company	None

Mr. Li Yuliang (李雨亮), aged 45, is the chairman of the Board, an executive Director and general manager of our Company. Please refer to "Board of Directors — Executive Directors" in this section for Mr. Li's biography.

Dr. Daniel Yunlong Du, aged 62, is the executive Director, deputy general manager and chief medical officer of our Company. Please refer to "Board of Directors — Executive Directors" in this section for Dr. Du's biography.

Mr. Wu Xing (毋興), aged 48, is the executive Director, chief financial officer, Board Secretary and one of the joint company secretaries of our Company. Please refer to "Board of Directors — Executive Directors" in this section for Mr. Wu's biography.

JOINT COMPANY SECRETARIES

Mr. Wu Xing (毋興), aged 48, is the executive Director, chief financial officer, Board secretary and one of the joint company secretaries of our Company. Please refer to "Board of Directors — Executive Directors" in this section for Mr. Wu's biography.

Ms. Sham Ying Man (岑影文), is one of our joint company secretaries. Ms. Sham is a senior manager of the Company Secretarial Services Division of Tricor Services Limited, a member of Vistra Group.

Ms. Sham has over 25 years of experience in the corporate secretarial field. Ms. Sham currently holds company secretary/joint company secretary positions in other companies listed on the Stock Exchange, including Hilong Holding Limited (海隆控股有限公司) (stock code: 01623.HK), Honma Golf Limited (本間高爾夫有限公司) (stock code: 06858.HK), WuXi Biologics (Cayman) Inc. (藥明生物技術有限公司) (stock code: 02269.HK), BrainAurora Medical Technology Limited (腦動極光醫療科技有限公司) (stock code: 06681.HK), Guming Holdings Limited (古茗控股有限公司) (stock code: 01364.HK), MetaLight Inc. (stock code: 02605.HK), FS.COM Limited (深圳市飛速創新技術股份有限公司) (stock code: 03355.HK) and UISEE Technologies (Beijing) Co., Ltd. (馭勢科技(北京)股份有限公司) (stock code: 01511.HK).

Ms. Sham obtained a bachelor degree in business administration from Lingnan College (now known as Lingnan University) in 1997. She is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom, respectively.

BOARD COMMITTEES

Our Board delegates certain responsibilities to various dedicated committees. In accordance with relevant PRC laws, regulations, the Articles and the Hong Kong Listing Rules, we have formed three Board committees, namely, the Audit Committee, the Remuneration Committee and the Nomination Committee.

Audit Committee

Our Company has established an audit committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and paragraph D.3 of the CG Code. The primary duties of our Audit Committee are to assist our Board in providing an independent view of the effectiveness of the financial reporting process, the internal control and risk management system of our Company, to oversee the audit process and to perform other duties and responsibilities as assigned by our Board. Our Audit Committee consists of three members, namely, Mr. Hu Wei (胡威), Mr. Zhang Qing (張青) and Mr. Na Shuai (那帥). Mr. Hu Wei (胡威) is the chairman of our Audit Committee. Mr. Hu Wei (胡威) possesses the appropriate accounting or related financial management expertise in compliance with the requirements under Rules 3.10(2) and 3.21 of the Listing Rules.

The primary duties of our Audit Committee are to (i) monitor and evaluate the work of the external auditor; (ii) evaluate the implementation of the internal audit system of our Company; (iii) responsible for the communications among the management level of our Company, the internal and external audit; (iv) review and comment on the financial reports of our Company; (v) examine the financial reporting system, risk management and internal control systems of our Company; (vi) make recommendations to our Company on the appointment, re-appointment and removal of the external auditor; (vii) perform daily management duties and implementing control on connected transactions; and (viii) perform such other duties determined by our Board.

Remuneration Committee

Our Company has established a remuneration committee with written terms of reference in compliance with Rule 3.25 of the Listing Rules and paragraph E.1.2 of the CG Code. Our Remuneration Committee consists of three members, namely, Mr. Lang Xiaofeng (郎曉峰) Mr. Hu Wei (胡威) and Mr. Wu Xing (毋興). Mr. Lang Xiaofeng (郎曉峰) is the chairman of our Remuneration Committee.

The primary duties of our Remuneration Committee include, but not limited to (i) establishing, reviewing and providing advices to our Board on our policy and structure concerning remuneration of our Directors and senior management and on the establishment of a formal and transparent procedure for developing policies concerning such remuneration; (ii) determining the terms of the specific remuneration package of each Director and senior management; (iii) reviewing and approving performance-based remuneration by reference to corporate goals and objectives resolved by our Directors from time to time; and (iv) reviewing and/or approving matters relating to share schemes under Chapter 17 of the Listing Rules.

Nomination Committee

Our Company has established a nomination committee with written terms of reference in compliance with paragraph B.3.1 of the CG Code and Rule 3.27A of the Listing Rules. Our Nomination Committee consists of three members, namely Mr. Na Shuai (那帥), Mr. Lang Xiaofeng (郎曉峰) and Ms. Wang Hongmei (王紅媚). Mr. Na Shuai (那帥) is the chairman of our Nomination Committee.

The primary duties of our Nomination Committee are to (i) review the structure, size and composition of our Board on a regular basis and make recommendations to our Board regarding any proposed changes to the composition of our Board; (ii) identify, select or make recommendations to our Board on the selection of individuals nominated for Directorship, and ensure the diversity of our Board members; (iii) assess the independence of our independent non-executive Directors; (iv) make recommendations to our Board on relevant matters relating to the appointment, re-appointment and removal of our Directors and succession planning for our Directors; and (v) support our Company's regular evaluation of the Board's performance.

MANAGEMENT PRESENCE IN HONG KONG

Since our headquarters and principal business operations and management of our Company are carried out in China, our executive Directors are based in China to better manage and attend to our Company's business operations. Therefore, we do not and, in the foreseeable future, will not have sufficient management presence in Hong Kong for the purpose of satisfying the requirement under Rule 8.12 of the Listing Rules. Pursuant to Rule 19A.15 of the Listing Rules, we [have applied] to the Stock Exchange for, and the Stock Exchange [has granted], a waiver from strict compliance with the requirement under Rule 8.12 and Rule 19A.15 of the Listing Rules. For details, please refer to the section headed "Waivers From Strict Compliance with the Hong Kong Listing Rules and Exemptions from Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance — Management Presence in Hong Kong" in this document.

CORPORATE GOVERNANCE

Our Directors recognize the importance of incorporating elements of good corporate governance in the management structures and internal procedures of our Company so as to achieve effective accountability and are committed to ensure the lawful, ethical and responsible operation of our Company's businesses. Our Company has adopted the code provisions stated in the CG Code, with internal compliance policies in place which set out our compliance requirements so as to ensure consistency with the code provisions stated in the CG Code.

Our Company is also committed to the view that our Board should include a balanced composition of executive Directors, non-executive Director and independent non-executive Directors so that there is a strong independent element on our Board, which can effectively exercise independent judgement.

As at the Latest Practicable Date, to the best of the knowledge, information and belief of our Directors having made all reasonable enquiries, save as the deviation from the code provision C.2.1 of Part 2 of the CG Code disclosed below, our Directors were not aware of any deviation from the code provisions of the CG Code as well as the Corporate Governance Guidance for Boards and Directors.

Mr. Li is the chairman of our Board and the general manager of our Company and he has been responsible for overall strategic planning of our Company and leading our Board since September 2016. Our Directors consider that vesting the roles of the chairman of our Board and the general manager of our Company in Mr. Li is beneficial to the management and business development of

our Company and will provide a strong and consistent leadership to our Company. Our Board will continue to review and consider splitting the roles of the chairman of our Board and the general manager at a time when it is appropriate and suitable by taking into account the circumstances of our Company as a whole.

Board Diversity Policy

Our Board has adopted a Board diversity policy which sets out the approach to achieve diversity on our Board. Our Company recognizes and embraces the benefits of having a diverse Board and sees increasing diversity at our Board level as an essential element in supporting the attainment of our Company's strategic objectives and sustainable development. Our Company seeks to achieve Board diversity through the consideration of a number of factors, including but not limited to talents, skills, gender, age, cultural and educational background, ethnicity, experience (professional or otherwise), independence, knowledge and length of service and any other factors that our Board may consider relevant and applicable from time to time. We will continue to implement measures and steps to promote and enhance gender diversity at all levels of our Company. We will select potential Board candidates based on merit and his/her potential contribution to our Board while taking into consideration our own business model and specific needs from time to time. All Board appointments will be based on meritocracy and candidates will be considered against objective criteria, having due regard to the benefits of diversity on our Board.

Our Directors, ranging from 38 years old to 62 years old, have a balanced mix of knowledge, skills and experience. They obtained degrees in various majors and possessed various working experience, including overall management and strategic development, business and risk management, and finance and accounting experience. The presence of female member in our management, namely Ms. Wang, contributes to the gender diversity of our management team and offers us valuable strategic, management and operational insights from female perspective. We have taken and will continue to take steps to promote gender diversity at all levels of our Company, including but without limitation at our Board level.

Our Nomination Committee is responsible for ensuring the diversity of our Board members. After [**REDACTED**], our Nomination Committee will review our Board diversity policy from time to time to ensure its continued effectiveness and we will disclose the implementation of our Board diversity policy in our corporate governance report on an annual basis.

Taking into account our existing business model and specific needs as well as the different background and abilities of our Directors, our Directors are of the view that the current composition of our Board satisfies the principles under our Board diversity policy.

COMPENSATION OF DIRECTORS AND SENIOR MANAGEMENT

Our Directors and members of our senior management receive compensation from our Company in the form of Directors' fee, salaries, allowances and benefits in kind, discretionary bonuses, retirement scheme contributions and equity-settled share-based payments. The aggregate remuneration (including Directors' fee, salaries, allowances and benefits in kind, discretionary bonuses, retirement scheme contributions and equity-settled share-based payments) to our Directors for the years ended December 31, 2024 and 2025 and the four months ended April 30, 2026 was RMB14.1 million, RMB17.8 million and RMB18.7 million, respectively. Save as disclosed above, no other amounts had been paid or were payable by any member of our Company to our Directors during the Track Record Period.

The aggregate amount of Directors' fee, salaries, allowances and benefits in kind, discretionary bonuses, retirement scheme contributions and equity-settled share-based payments to our five highest paid individuals, excluding two, two and two Directors for the years ended December 31, 2024 and 2025 and the four months ended April 30, 2026 was RMB6.5 million, RMB8.0 million and RMB6.5 million, respectively.

No remuneration was paid by us to our Directors or the five highest paid individuals as an inducement to join or upon joining us or as a compensation for loss of office during the Track Record Period. There was no arrangement under which our Directors had waived or agreed to waive any remuneration during the same periods.

Under the arrangement currently in force, the aggregate remuneration (including Directors' fee, salaries, allowances and benefits in kind, discretionary bonuses, retirement scheme contributions and equity-settled share-based payments) of our Directors for the year ending December 31, 2026 is estimated to be no more than RMB37.8 million.

Our Board will review and determine the remuneration and compensation packages of our Directors and senior management which, following the [**REDACTED**], will receive recommendation from our Remuneration Committee which will take into account salaries paid by comparable companies, time commitment and responsibilities of our Directors and senior management and performance of our Company.

DISCLOSURE UNDER RULE 8.10(2) OF THE LISTING RULES

Set out below are interests of our Directors in businesses which may compete with our business for the purpose of Rule 8.10(2) of the Hong Kong Listing Rules as of the Latest Practicable Date:

Disclosable interest of Mr. Li

As of the Latest Practicable Date, Mr. Li held certain interest in other healthcare companies. For details, please refer to the section headed "Relationship with Our Controlling Shareholders" in this document.

Disclosable interest of Dr. Han

As of the Latest Practicable Date, Dr. Han held certain non-executive directorships and minority shareholdings in other healthcare companies. Dr. Han serves as a non-executive director in BroadenBio Co., Ltd. (北京伯匯生物技術有限公司) ("**BroadenBio**") and Yikun Xingjian Biomedical (Shanghai) Co., Ltd. (宜坤行健生物醫藥(上海)有限公司) ("**Yikun Xingjian**") (BroadenBio and Yikun Xingjian are collectively referred as "**Lapam-Invested Entities**") by virtue of Dr. Han's position as a member of the investment committee at Lapam Group. Besides, Dr. Han is a shareholder of less than 5% of Zhejiang Ruizhen Pharmaceutical Co., Ltd. (浙江瑞臻醫藥有限公司) ("**Zhejiang Ruizhen**"), is a company primarily engaged in research and development of oncology.

As confirmed by Dr. Han, despite Dr. Han (i) serves as a non-executive director in these Lapam-Invested Entities and (ii) holds less than 5% shareholding interest in Zhejiang Ruizhen, he is not involved in the day-to-day management of the any of the Lapam-Invested Entities and thus is unable to exert control on any of these companies. As a member of the investment committee at Lapam Group, Dr. Han is only a passive investor in the Lapam-Invested Entities. Further, he is not involved in the management and investment decision-making of Lapam-Invested Entities and Zhejiang Ruizhen, and he has no control over the composition of the board of directors of these companies, and is not involved in the daily management and operation of the above investee companies. In addition, to ensure proper separation of duties and prevent the flow of sensitive information between the biotechnology companies, a group-level "Chinese Wall" policy has been developed to incorporate objectives and principles to identify and manage actual or potential conflicts of interests which may arise between the Company's interests and Dr. Han's involvement in the other biotechnology companies, while allowing oversight of the Board by the Company. The Chinese Wall protocol generally prohibits the unauthorized sharing of non-public, confidential and sensitive information between us and the relevant biotechnology companies, subject to limited necessary specified exceptions on a strict need-to-know basis. To avoid potential conflicts of

interest and to ensure that the advice provided by Dr. Han and adopted by our Company will be in the best interest of our Company and the Shareholders as a whole, the advice provided by Dr. Han will be scrutinized independently by our Company and all major decisions will be made in consultation with members of our Board, including our independent non-executive Directors who will offer independent advice to our Board. Given that Dr. Han is not one of our Controlling Shareholders, the Directors are of the view that his interest in such companies would not render us incapable of carrying on our business independently from the other companies in which he may hold directorships or shareholding from time to time.

Save for Mr. Li and Dr. Han's respective interests in the above entities and save as disclosed in this document, as of the Latest Practicable Date, no Controlling Shareholder, Director or any of their respective close associates had any interest in any other business apart from the business operated by our Company, which competes, or is likely to compete, either directly or indirectly, with the business of our Company and would require disclosure pursuant to Rule 8.10 of the Listing Rules.

COMPLIANCE ADVISER

In compliance with Rule 3A.19 of the Hong Kong Listing Rules, we have appointed Patrons Capital Limited as our compliance adviser to provide advisory services to our Company. Pursuant to Rule 3A.23 of the Hong Kong Listing Rules, it is expected that the compliance adviser will, amongst other things, advise our Company with due care and skill in the following circumstances:

- before the publication of any regulatory announcement, circular and financial report;
- where a transaction, which might be notifiable or connected transaction, is contemplated including shares issues, sales or transfers of treasury shares and share repurchases;
- where we propose to use the [**REDACTED**] from the [**REDACTED**] in a manner different from that detailed in this document or where our business activities, developments or results of our Company deviate from any forecast, estimate, or other information in this document; and
- where the Hong Kong Stock Exchange makes an inquiry of us regarding unusual movements in the price or [**REDACTED**] of the Share securities, the possible development of a false market in this Shares, or any other matters in accordance with Rule 13.10 of the Hong Kong Listing Rules.

The term of the appointment shall commence on the [**REDACTED**] and end on the date on which we distribute our annual report in respect of our financial results for the first full financial year commencing after the [**REDACTED**] and such appointment may be subject to extension by mutual agreement.